《新股消息》现代中药(01643.HK)每股定价1.18元 一手中签率10%
现代中药(01643.HK)公布招股结果,发售价定於1.18元,略低於招股范围(介乎每股0.92至1.47元)中间价,公开发售录超购29.66倍,经重新分配後,公开发售股数增至30%。每手3,000股,中签率为10%。该股将於明日(15日)上市。独家保荐人为东吴证券。
公司预计,所得款项净额约为1.17亿元,当中44%用作扩大产能;16.8%用於扩大华南及华东的分销网络;10.2%用於透过媒体营销及推广活动提升品牌知名度;19.9%用於加大研发力度、采购质量管理设备及扩大产品组合;3.4%用於升级IT系统;以及5.7%用於一般营运用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.